

**Curriculum vitae**  
**SIMONA CORSO**

**Personal details**

Born in Torino, January 7th 1977

Nationality: Italian

Email: [simona.corso@unito.it](mailto:simona.corso@unito.it)

Website: <https://www.oncology.unito.it/do/docenti.pl/Alias?simona.corso#tab-profilo>

ORCID ID: 0000-0002-5069-1503;

Scopus ID: 7004136805;

Researcher ID: DWR-2780-2022

**Educations**

Jan2011-Dec 2020:

Assistant professor (SSD: BIO/17), Dep. Of Oncology, University of Torino, at Candiolo Cancer Institute, FPO-IRCCS

Feb 2006 to Dec2010:

Postdoctoral Fellow, Candiolo Cancer Institute, School of Medicine, University of Torino.

Nov 2001 to Jan 2006:

PhD in Cell Science and Technology, Division of Molecular Oncology, University of Torino.

Sep 1996 to July 2001:

Master (5-year course) in Medical Biotechnology (full marks and exceptional honors, thesis publication), School of Medicine, University of Torino

**Professional experiences and current position**

**CURRENT POSITION**

Associate professor (SSD: BIOS/13), Dep. Of Oncology, University of Torino, at Candiolo Cancer Institute, FPO-IRCCS, from December 2020.

**RESEARCH EXPERIENCE**

2020-today: Associate professor (SSD: BIOS/13), at the University of Torino. Current subjects: Identifying and targeting gastric cancer persister cell vulnerabilities to fight tumor chemoresistance.

2010-2020: Assistant professor (SSD: BIO/17), at the University of Torino. Interruption of the research from May to October 2011 for maternity leave. Current subjects: Generation of a platform of gastro-esophageal PDXs to identify and validate molecular targets; Metabolic-driven, non-cell-autonomous, adaptive response to target therapies.

2008-2010: Postdoc fellow in the Department of Oncological Sciences of Candiolo Cancer Institute. Recipient of a Research Fellowship of the University of Torino. Interruption of the research from May to October 2009 for maternity leave. Subject: Mechanisms of resistance to MET targeted therapies: the role of HER family members.

2007-2008: Postdoc fellow in the Division of Molecular Oncology of Candiolo Cancer Institute, University of Torino. Recipient of an AIRC fellowship. Subject: Cancer 'addiction' to the MET oncogene

2005-2006: Postdoc fellow in the Department of Oncological Sciences of the Candiolo Cancer Institute, University of Torino. Recipient of a Research Fellowship of the University of Torino. Subject: Cancer 'addiction' to the MET oncogene.

2001-2005: Ph.D course in Cellular Sciences and Technologies in the Department of Oncological Sciences of the Candiolo Cancer Institute. Subject: Functional interaction among MET and other transmembrane receptors, and role of MET during cancer progression.

2005: Visiting fellow at the Department of Surgical and Oncological Disciplines of Palermo. Supervisor: Prof. Stassi. Subject: Study of the role of MET in progenitor stem cells.

2003: Visiting fellow in the "Gulbenkian Institute for Science", Lisbon (Portugal). Supervisor: Dr. Maria Mota. Subject: Role of HGF/Met in malaria infection

1998-2001: Research training as undergraduate student at the Candiolo Cancer Institute, Candiolo. Subject: Identification of a ligand-independent, alternative mechanism of MET activation, mediated by the interaction between MET and Class B Plexins.

### **Honors**

Winner of the European Association Cancer Research "2006 MDS-EACR Research Award", during the "19th Meeting of the European Association for Cancer Research", Budapest (Hungary).

### **Teaching activity:**

2003 to present: Supervisor of: 7 POSTDOCTORAL FELLOWS; 6 PHD STUDENTS; 4 MASTER STUDENTS

2019 to present: Member of the 'PhD in Molecular Medicine' Commission, University of Torino.

2021 to present: Assigned Course of Histology and Embryology, Degree Course in Medicine and Surgery of Torino, 'Canale B', School of Medicine, University of Torino.

2020 to present: Assigned Course in Human Histology to Nursing undergraduate students, San Luigi Gonzaga, Orbassano- Branch, University of Torino.

2011 to 2020: Assigned Course in Human Histology to Nursing undergraduate students (Canale A and Canale B), San Luigi Gonzaga, Cuneo- Branch, University of Torino.

2016 to present: Integrated Course of 'Bases of Human Morphology', English Degree Course in Medicine and Surgery at San Luigi Gonzaga Hospital, Orbassano, School of Medicine, University of Torino. Responsible of the Histology Clerkship.

2010 to 2015: Integrated Course of 'Basi di Morfologia Umana', Degree Course in Medicine and Surgery at San Luigi Gonzaga Hospital, Orbassano, School of Medicine, University of Torino.

2002 to 2010: Integrated Course of Histology and General Embryology, Degree Course in Medicine and Surgery at San Luigi Gonzaga Hospital, Orbassano, School of Medicine, University of Torino

Oct 2002 to Nov 2011 Course in Human Histology to Nursing undergraduate students, University of Torino

Oct 2007 to Nov 2013: Course in Human Histology to Physiotherapy undergraduate students, University of Torino.

### **Research main topics**

Dr. Corso has been working on targeted therapies and resistance for more than 20 years, with a particular focus, in the last years, on gastric cancer, acquiring high competence and qualification in this field.

Main research achievements:

1) She developed one of the first inducible systems for short-hairpin RNAs, through which she demonstrated that tumors bearing MET gene amplification are "MET-addicted" throughout all the stages of tumor progression: Corso S., et al (2008) *Silencing the MET oncogene leads to regression of experimental tumors and metastases*. ONCOGENE (**First Author**).

2) She identified cell-autonomous mechanisms of resistance to MET tyrosine kinase inhibitors and to anti-MET monoclonal antibodies: Corso S., et al. (2010) *Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition*; MOLECULAR CANCER (**First Author**); Martin, V., Corso S., et al. (2014) *Increase of met gene copy number confers resistance to a monovalent met antibody and establishes drug dependence*. MOLECULAR ONCOLOGY (**Corresponding author**).

3) She discovered that amplification of the MET proto-oncogene is responsible for de novo and acquired resistance to anti-EGFR therapy in a subset of colorectal cancers, opening novel opportunities to design clinical studies: Bardelli A\*, Corso S\*, et al. (2013) *Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer*. CANCER DISCOVERY (**First co-author**).

4) In the frame of her AIRC IG 2018, she recently discovered a novel, metabolism based, non-cell-autonomous mechanism of resistance to different TKIs. Apicella M, Corso S. (2018) *Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies*. CELL METABOLISM (**Last Author**); Ughetto et al (2021), *Personalized therapeutic strategies in HER2-driven gastric cancer*. GASTRIC CANCER; (**Co-last author**); Rizzolio et al (2022), *The importance of being CAFs (in cancer resistance to targeted therapies)*, J EXP CLIN CANCER RES (**Last Author**).

5) In collaboration with Prof. Giordano, she has recently generated a molecularly annotated platform of gastric Patient-Derived Xenografts (at present, the widest gastric PDX platform generated in an academic institution). This platform allowed the identification of several new molecular targets in gastric cancer: S. Corso et al (2019) *A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits*. CANCER RESEARCH (**First and Corresponding author**). Corso S, et al. (2018) *Rituximab treatment prevents lymphoma onset in gastric cancer Patient-Derived-Xenografts*. NEOPLASIA (**First author**); Apicella M. et al. (2017), *'Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort'* ONCOGENE (**Co-Last and Corresponding author**). Corso et al. (2021), *Optimized EGFR blockade strategies in EGFR addicted gastroesophageal cancer*, CLINICAL CANCER RESEARCH (**First and Corresponding author**).; Pietrantonio et al, (2022) *'HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial'*, CLINICAL CANCER RESEARCH; Petrelli et al, (2023), *'BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors'*, CANCER RESEARCH (**Co-Corresponding author**); Piliga et al (2024), *'Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models'*, GASTRIC CANCER; Conticelli et al (2025), *'AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer*, CANCER RESEARCH' (**Co-Corresponding author**).

### Main projects as PI:

Study of non-cell-autonomous mechanism of resistance to targeted therapies (Apicella M, Corso S. (2018) *Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies*. CELL METABOLISM (**Last Author**); Ughetto et al (2021), *Personalized therapeutic strategies in HER2-driven gastric cancer*. GASTRIC CANCER; (**Co-last author**); Rizzolio et al (2022), *The importance of being CAFs (in cancer resistance to targeted therapies)*, J EXP CLIN CANCER RES (**Last Author**). She was **Invited Speaker at the EMBO Workshop**. 'Lactate: Unconventional roles of a nutrient along tumor landscape', June 21-23, 2021).

- Identification of novel vulnerabilities in gastric cancer : S. Corso et al (2019) *A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits*. CANCER RESEARCH (**First and Corresponding author**). Corso S, et al. (2018) *Rituximab treatment prevents lymphoma onset in gastric cancer Patient-Derived-Xenografts*. NEOPLASIA (**First author**); Apicella M. et al. (2017), *'Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort'* ONCOGENE (**Co-Last and Corresponding author**). Corso et al. (2021), *Optimized EGFR blockade strategies in EGFR addicted gastroesophageal cancer*, CLINICAL CANCER RESEARCH (**First and Corresponding author**).; Pietrantonio et al, (2022) *'HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial'*, CLINICAL CANCER RESEARCH; Petrelli et al, (2023), *'BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors'*, CANCER RESEARCH (**Co-Corresponding author**): Puliga et al (2024), *'Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models'*, GASTRIC CANCER; Conticelli et al (2025), *'AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer*, CANCER RESEARCH ' (**Co-Corresponding author**).

### Bibliometry (2002-2025) ([www.scopus.com](http://www.scopus.com))

- Cumulative Impact Factor (IF) sums to 654,636 (average IF 11,92);
- Total IF of publications as First, Last or Corresponding Author: 289,936 (average IF: 13,806);
- Total IF of publications as Last or Corresponding Author: 257,336 (average IF: 15,137).
- Total citations: 4,855 Citations by 4,074 documents
- H index 34

### 10 best publications

1) AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer. Conticelli D, Volante M, Pietrantonio F, Orrù C, Olivero M, Nottegar A, Borghi F, Baiocchi GL, Crotti G, Fumagalli Romario U, De Manzoni G, Reddavid R, Porporato R, Kılıç D, Ghione R, Calabrò E, Petty R, Corso S, Giordano S, Migliore C. CANCER RESEARCH 2025 Aug 15;85(16):3111-3122. Authorship: Co-corresponding Author (IF: 16,6)

2) BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors  
Annalisa Petrelli\*‡, Sabrina Rizzolio\*, Filippo Pietrantonio; Sara E. Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orru', Salvatore Ribisi, Daniel Moya-Rull,

Cristina Migliore<sup>1</sup>; Daniela Conticelli, Irene M. Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop-Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore-Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli Romario, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F. Amisano, Alessandro Ferrero, Caterina Marchiò, Simona Corso, Silvia Giordano

CANCER RESEARCH 2023, 83(10), pp. 1699–1710. Authorship: Co-corresponding Author (IF: 16.6)

3) Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas.

Corso S, Pietrantonio F, Apicella M, Migliore C, Conticelli D, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli Romario U, de Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, de Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, Morano F, Corallo S, Prisciandaro M, Di Bartolomeo M, Gloghini A, Marsoni S, Sottile A, Sapino A, Marchiò C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB, Giordano S

CLIN CANCER RES 2021 Jun; 27: 3126 | PMID: 33542076 Authorship: First and Co-corresponding Author (IF: 10.2)

4) A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits.

Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, Ughetto S, D'Errico L, Menegon S, Moya-Rull D, Cargnelutti M, Capelôa T, Conticelli D, Giordano J, Venesio T, Balsamo A, Marchiò C, Degiuli M, Reddavid R, Fumagalli U, De Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Pietrantonio F, Morano F, Siena S, Sartore-Bianchi A, Bencivenga M, Mengardo V, Rosati R, Marrelli D, Morgagni P, Rausei S, Pallabazzer G, De Simone M, Ribero D, Marsoni S, Sottile A, Medico E, Cassoni P, Sapino A, Pectasides E, Thorner AR, Nag A, Drinan SD, Wollison BM, Bass AJ, Giordano S

CANCER RES 2019 Nov; 79: 5884 | PMID: 31585941 Authorship: First and corresponding Author (IF: 16.6)

5) Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies.

Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E, Pietrantonio F, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S

CELL METAB 2018 Dec; 28: 848 | PMID: 30174307 Authorship: Last and corresponding Author (IF: 30.9)

6) Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, Sapino A, Sottile A, Sarotto I, Casorzo L, Cassoni P, De Simone M, Comoglio PM, Marsoni S, Corso S\*, Giordano S\*. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

ONCOGENE 2017. 36(9): 1200-10. DOI:10.1038/onc.2016.283 Authorship: Co-Last and corresponding Author (IF: 7.3)

7) Corso S§ and Giordano S§. Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective.

CANCER DISCOVERY 2013. 3(9): 978-92. DOI:10.1158/2159-8290.CD-13-0040 Authorship: Co-Corresponding Authors (IF: 33.3)

8) Bardelli A\*, Corso S\*, Bertotti A\*, Hobor S\*, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T,

Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. *CANCER DISCOVERY* 2013. 3(6): 658-73. DOI:10.1158/2159-8290.CD-12-0558 Authorship: Co-First Author. (IF: 33,3)

9) Corso S\*, Ghiso E\*, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. *MOLECULAR CANCER* 2010. 26(9): 121. DOI:10.1186/1476-4598-9-121 Authorship: Co-First and corresponding Author. (IF: 33,9)

10) Giordano S, Corso S, Conrotto P, Artigiani S, Barberis D, Tamagnone L and Comoglio PM. Semaphorin 4D receptor controls invasive growth by coupling with Met tyrosine kinase. *NATURE CELL BIOLOGY* 2002. 4(9): 720-24. DOI:10.1038/ncb843 (IF: 19,1)

### **15 more relevant publication in the last 5 yrs (2020- 2025)**

1. AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer. Conticelli D, Volante M, Pietrantonio F, Orrù C, Olivero M, Nottegar A, Borghi F, Baiocchi GL, Crotti G, Fumagalli Romario U, De Manzoni G, Reddavid R, Porporato R, Kılıç D, Ghione R, Calabrò E, Petty R, Corso S, Giordano S, Migliore C. *CANCER RESEARCH* 2025 Aug 15;85(16):3111-3122. PMID: 40637454
2. Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations. D'Ambrosio A, Bressan D, Ferracci E, Carbone F, Mulè P, Rossi F, Barbieri C, Sorrenti E, Fiaccadori G, Detone T, Vezzoli E, Bianchi S, Sartori C, Corso S, Fukuda A, Bertalot G, Falqui A, Barbareschi M, Romanel A, Pasini D, Chiacchiera F. *SCI ADV.* 2024 Mar 15;10(11): eadh4435. PMID: 38489371
3. Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair. Ballout F, Lu H, Bhat N, Chen L, Peng D, Chen Z, Chen S, Sun X, Giordano S, Corso S, Zaika A, McDonald O, Livingstone AS, El-Rifai W. *CLIN CANCER RES.* 2024 May 15;30(10):2193-2205. PMID: 38592373
4. Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models. Puliga E, De Bellis C, Vietti Michelina S, Capeloa T, Migliore C, Orrù C, Baiocchi GL, De Manzoni G, Pietrantonio F, Reddavid R, Fumagalli Romario U, Ambrogio C, Corso S, Giordano S. *GASTRIC CANCER.* 2024 May; 473-483. PMID: 38261067
5. International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape: Bertinoro Workshop, November 2022. Morgagni, P., Bencivenga, M., Carneiro, F., ... Wojciech, K., Thortsen, G, Bertinoro Workshop Working Group. *GASTRIC CANCER,* (2024), 27, 4, (649-671). PMID: 38634954
6. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio; Sara E. Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orru', Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore1; Daniela Conticelli, Irene M. Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop-Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore-Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli Romario, Giovanni De Manzoni,

Maurizio Degiuli, Gian Luca Baiocchi, Marco F. Amisano, Alessandro Ferrero, Caterina Marchiò, Simona Corso, Silvia Giordano  
CANCER RESEARCH 2023 May 15;83(10):1699-1710 PMID: 37129948 Authorship: Co-corresponding Author

7. HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial. Pietrantonio F, Manca P, Bellomo SE, Corso S, Raimondi A, Berrino E, Morano F, Migliore C, Niger M, Castagnoli L, Pupa SM, Marchiò C, Di Bartolomeo M, Restuccia E, Lambertini C, Tabernero J, Giordano S  
CLIN CANCER RES 2023 Feb; 29: 571 | PMID: 36413222
8. Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. Castagnoli L, Corso S, Franceschini A, Raimondi A, Bellomo SE, Dugo M, Morano F, Prisciandaro M, Brich S, Belfiore A, Vingiani A, Di Bartolomeo M, Pruneri G, Tagliabue E, Giordano S, Pietrantonio F, Pupa SM  
CELL ONCOL 2023 Feb | PMID: 36753044
9. hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers. Martinelli I, Modica C, Chiriaco C, Basilico C, Hughes JM, Corso S, Giordano S, Comoglio PM, Vigna E  
J EXP CLIN CANC RES 2022 Mar; 41: 112 | PMID: 35351166
10. The importance of being CAFs (in cancer resistance to targeted therapies). Rizzolio S, Giordano S, Corso S  
J EXP CLIN CANC RES 2022 Nov; 41: 319 | PMID: 36324182. Authorship: Last Author
11. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshov JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, ,  
NAT GENET 2021 Jan; 53: 86 | PMID: 33414553
12. Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas. Corso S, Pietrantonio F, Apicella M, Migliore C, Conticelli D, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli Romario U, de Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, de Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, Morano F, Corallo S, Prisciandaro M, Di Bartolomeo M, Gloghini A, Marsoni S, Sottile A, Sapino A, Marchiò C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB, Giordano S  
CLIN CANCER RES 2021 Jun; 27: 3126 | PMID: 33542076 Authorship: Co-corresponding Author
13. Personalized therapeutic strategies in HER2-driven gastric cancer. Ughetto S, Migliore C, Pietrantonio F, Apicella M, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Rizzolio S, Capelôa T, Ribisi S, Degiuli M, Reddavid R, Rapa I, Fumagalli U, De Pascale S, Ribero D, Baronchelli C, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Manenti S, Bencivenga M, Sacco M, Castelli C, Siena S, Sartore-Bianchi A, Tosi F, Morano F, Raimondi A, Prisciandaro M, Gloghini A, Marsoni S, Sottile A, Sarotto I, Sapino A, Marchiò C, Cassoni P, Guarrera S, Corso S, Giordano S  
GASTRIC CANCER 2021 Jul; 24: 897 | PMID: 33755862 Authorship: Co-last Author

14. Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells. Rizzolio S, Corso S, Giordano S, Tamagnone L  
CANCERS 2020 Aug; 12: | PMID: 32784465
15. Patient-Derived Cancer Models. Di Renzo MF, Corso S  
CANCERS 2020 Dec; 12: | PMID: 33333972 Authorship: Last Author